- Omeros (NASDAQ:OMER +0.9%) announces that Omidria (phenylephrine and ketorolac injection) is now commercially available throughout the U.S. It is indicated for administration during cataract surgery and other intraocular lens replacement procedures to prevent intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.
- The nationwide launch follows a two-month controlled launch which allowed the company to refine its commercial processes.
- The FDA approved Omidria in June of last year. The European Medicines Agency's review is ongoing.